medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2018, Número 1

Rev Invest Clin 2018; 70 (1)


Heading toward the elimination of Hepatitis C virus

Kershenobich D, Torre-Delgadillo A, Aguilar-Valenzuela LM

Idioma: Inglés.
Referencias bibliográficas: 7
Paginas: 29-31
Archivo PDF: 128.24 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244:362-4.

  2. Jackson WE, Everson GT. Sofosbuvir and velpatasvir for the treatment of hepatitis C. Expert Rev Gastroenterol Hepatol. 2017;11:501-5.

  3. Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67:263-71

  4. WHO. Hepatitis C Fact Sheet. Updated October, 2017 Geneva: WHO; 2017.

  5. Grebely J, Applegate TL, Cunningham P, Feld JJ. Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. Expert Rev Mol Diagn. 2017;17:1109-15.

  6. Morgan JR, Servidone M, Easterbrook P, Linas BP. Economic evaluation of HCV testing approaches in low and middle income countries. BMC Infect Dis. 2017;17:697.

  7. Gunter J, Chirino-Sprung RA, Méndez-Sánchez N, et al. Cost Analysis of Strategies to Control the Disease Burden of Chronic Hepatitis C Virus (HCV) Infection in Mexico. AASLD, Poster No. 171003; 2017.




2020     |     www.medigraphic.com